In This Section

Program

Please note that this meeting will take place as an in-person event in Boston and will not live-stream content for virtual participation. The meeting content will be recorded and made available as an on-demand program after the conference. Please see the registration page for details.

CME credit is available for in-person attendance for the designated sessions. On-demand presentations are not eligible for CME.

All presentations are scheduled to be live, in-person presentations at the date and time specified below unless noted otherwise. Program in progress.

*-Short talk from proffered abstract

Friday, october 18

saturday, october 19

sunday, october 20

monday, october 21

Friday, October 18

Registration

3-8 p.m. | American Ballroom Foyer

Welcome and Opening Keynote

6:30-7:30 p.m. | America Ballroom North | CME Eligible

  • 6:30 p.m. | Welcome and Introduction of Keynote Speaker
    Yvonne Y. Chen, University of California, Los Angeles, California
  • 6:35 p.m. | Keynote Lecture
    Susan M. Kaech, Salk Institute for Biological Studies, La Jolla, California
  • 7:15 p.m. | Discussion / Q&A

OPENING RECEPTION

7:30-9:30 p.m. | America Ballroom South

Saturday, October 19

CONTINENTAL BREAKFAST

7-8 a.m. | American Ballroom Foyer

Plenary Session 1: Good and Bad CD4 T cell Help

8-10:05 a.m. | America Ballroom North | CME Eligible

Session Chair: Sergio Quezada, University College London (UCL) Cancer Institute, London, England

  • 8:05 a.m. | Cancer biomarker defining the subset of HPV16+ head and neck cancer patients benefiting from therapeutic vaccine combination with anti-PD-1
    Cornelis JM Melief, ISA Pharmaceuticals, Oegstgeest, Netherlands
  • 8:35 a.m. | Treg targeting at the interface of adaptive and innate immunity-targetable bad help
    Sergio Quezada
  • 9:05 a.m. | Tr1 as major inhibitors of anti-tumor responses-bad help
    Robert D. Schreiber, Washington University School of Medicine in St. Louis, St. Louis, Missouri
  • 9:35 a.m. | Distinct CD4+ T cell subpopulations as predictive biomarkers for anti-PD-1 and chemotherapy response in advanced NSCLC*
    Kenneth J. Gollob, Hospital Israelite Albert Einstein, Sao Paulo, Brazil
  • 9:50 a.m. | Panel Discussion

BREAK

10:05-10:25 a.m. | American Ballroom Foyer

Plenary Session 2: Mass Spectrometry / MHC

10:25-12:15 p.m. | America Ballroom North | CME Eligible

Session Chair: Michal Bassani Sternberg, University of Lausanne, Lausanne, Switzerland

  • 10:30 a.m. | Using FAIMS to improve detection of tumor neoantigens
    Cheryl Lichti, Washington University School of Medicine in St. Louis, St. Louis, Missouri
  • 11 a.m. | Insight into PTM-driven antigenicity
    Yifat Merbl, Wiezmann Institute of Science, Rehovat, Israel
  • 11:30 a.m. | Immunopeptidomic-driven exploration of the tumor antigenic landscape
    Michal Bassani Sternberg
  • 12 p.m. | Panel Discussion

Lunch on own

12:15-2:15 p.m.

Plenary Session 3: T-cell Engineering / Cellular Therapy

2:15-4:25 p.m. | America Ballroom North | CME Eligible

Session Chair: Yvonne Y. Chen, University of California, Los Angeles, California

  • 2:20 p.m. | Engineering multi-pronged CAR-T cell therapy for solid tumors
    Yvonne Y. Chen, University of California, Los Angeles, California
  • 2:50 p.m. | Utilizing insights from signaling biology to engineer CAR T cells
    Robbie G. Majzner, Dana-Farber Cancer Institute, Boston, Massachusetts
  • 3:20 p.m. | Fourth generation CAR-Tregs
    Megan Levings, BC Children’s Hospital Research Institute, Vancouver, BC, Canada
  • 3:50 p.m. | Competition for dendritic cells limits engineered TCR-T cell activation in tumor-draining lymph nodes and impairs synergy with PD-L1 blockade*
    Sam Nutt, Fred Hutchinson Cancer Center, Seattle, Washington
  • 4:05 p.m. | Panel Discussion

Cancer Immunology (CIMM) Working Group Session: Novel Approaches in Antigen Target Discovery

4:30-5:30 p.m. | America Ballroom North | CME Eligible

Session Chair: Catherine J. Wu, Dana-Farber Cancer Institute, Boston, Massachusetts

  • 4:30 p.m. | Genomic and immunoproteomic approaches for neoantigen discovery
    Catherine J. Wu
  • 4:45 p.m. | Decoding the autoantibody reactome in cancer immunotherapy
    Aaron Ring, Fred Hutchinson Cancer Center, Seattle, Washington
  • 5 p.m. | Functional decoding of anti-tumor T cell immunity using genetic screens
    Wouter Scheper, Netherlands Cancer Institute, Amsterdam, Netherlands
  • 5:15 p.m. | Panel Discussion

Poster Session A/reception

5:30-7:45 p.m. | America Ballroom South

Sunday, October 20

CONTINENTAL BREAKFAST

7-8 a.m. | American Ballroom Foyer

Plenary Session 4: New Checkpoints and Combinations

8-10:10 a.m. | America Ballroom North | CME Eligible

Session Chair: Fernando Vidal-Vanaclocha, The George Washington University, Washington, DC

  • 8 a.m. | Distinct immune checkpoint gene signatures of breast cancer subtypes with and without HER2-regulated stromal cell genes
    Fernando Vidal-Vanaclocha
  • 8:10 a.m. | Rational immunotherapy approaches based on the tumor glycolytic state
    Roberta Zappasodi, Weill Cornell Medicine, New York, New York
  • 8:40 a.m. | PD1-IL2v: PD-1-Cis IL-2Rbg agonism yields better T cell effectors from stem-like CD8+ T cells
    Laura Codarri, Roche, Schlieren, Switzerland
  • 9:10 a.m. | A TROP2/Claudin program mediates immune exclusion to impede checkpoint blockade in breast cancer*
    Bogang Wu, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts
  • 9:25 a.m. | Panel Discussion

BREAK

9:40-10:15 a.m. | American Ballroom Foyer

Plenary Session 5: Vaccines

10:15 a.m.-12:20 p.m. | America Ballroom North | CME Eligible

Session Chair: Robert D. Schreiber, Washington University School of Medicine in St. Louis, St. Louis, Missouri

In honor of Dr. Jeffrey S. Weber

  • 10:20 a.m. | New results on SLP-based neoantigen-targeting vaccines
    Catherine J. Wu, Dana-Farber Cancer Institute, Boston, Massachusetts
  • 10:50 a.m.| Personalized RNA vaccines for pancreatic cancer
    Vinod P. Balachandran, Memorial Sloan Kettering Cancer Center, New York, New York
  • 11:20 a.m. | Nous-209 off-the-shelf vaccine targets neoantigens mutations well represented both in primary and metachronous incident CRCs from Lynch syndrome patients*
    Lorenzo De Marco, Nouscom Srl, Rome, Italy
  • 11:35 a.m. | Personalized RNA neoantigen vaccines induce long-lived CD8+ T effector cells in pancreatic cancer*
    Pablo Guasp, Memorial Sloan Kettering Cancer Center, New York, New York
  • 11:50 a.m. | Optimally designed mRNA vaccine encoding tumor-specific antigens identified in a colorectal cancer model leads to complete tumor rejection in mice*
    Marie-Pierre Hardy, University of Montreal, Montreal, QC, Canada
  • 12:05 p.m. | Panel Discussion

LUNCH BREAK (ON YOUR OWN) 

12:20-2:30 p.m.

Plenary Session 6: Emerging Technologies, Microbiome, and Immunometabolism

2:30-4:35 p.m | America Ballroom North | CME Eligible

Session Chair: Greg M. Delgoffe, University of Pittsburgh, Pittsburgh, Pennsylvania

  • 2:35 p.m. | Spatial transcriptomics and novel insights into the immune tumor microenvironment
    Thomas F. Gajewski, University of Chicago, Chicago, Illinois
  • 3:05 p.m. | Targeting the gut microbiome for cancer immunotherapy
    Giorgio Trinchieri, National Cancer Institute, Bethesda, Maryland
  • 3:35 p.m. | Leveraging metabolic reprogramming to improve cellular therapies for cancer
    Greg M. Delgoffe
  • 4:05 p.m. | Spatial transcriptomics to profile the non-small cell lung cancer tumor microenvironment and identify novel predictive biomarkers for checkpoint blockade*
    Christina Cho, Yale University School of Medicine, New Haven, Connecticut
  • 4:20 p.m. | Panel Discussion

break

4:35-4:50 p.m. | American Ballroom Foyer

Keynote Lecture

4:50-5:50 p.m. | America Ballroom North | CME Eligible

  • 4:50 p.m. | Introduction of Keynote Speaker
    Robert D. Schreiber, Washington University School of Medicine in St. Louis, St. Louis, Missouri
  • 4:55 p.m. | Large-scale mapping of TCR-pMHC interactions
    Ton Schumacher, Netherlands Cancer Institute, Amsterdam, Netherlands
  • 5:35 p.m. | Discussion / Q&A

Poster Session B/reception

6-8:15 p.m. | America Ballroom South

Monday, October 21

CONTINENTAL BREAKFAST

7-8 a.m. | American Ballroom Foyer

Plenary Session 7: Myeloid and NK Cells

8-9:50 a.m. | America Ballroom North | CME Eligible

Session Chair: Matthew Spitzer, University of California, San Francisco, California

  • 8:05 a.m. | Retroviral mimics costimulate TLR7/8/9 for enhanced activation of dendritic cells and myeloid cells to induce anti-tumor CD8+ T cells
    Arthur M. Krieg, University of Massachusetts Chan Medical School, Needham, Massachusetts
  • 8:35 a.m. | Aire-expressing tumor-associated macrophages promote cancer immune evasion
    Matthew Spitzer, University of California, San Francisco, California
  • 9:05 a.m. | Oncogenic Ras dosage alters senescent immune response and influences tumour initiation*
    Haoran Zhu, CRUK Cambridge Institute, Cambridge, England
  • 9:20 a.m. | AXL limits the mobilization of cholesterol to regulate dendritic cell maturation and the immunogenic response to cancer*
    Meriem Belabed, Icahn School of Medicine at Mount Sinai, New York, New York
  • 9:35 a.m. | Panel Discussion

BREAK

9:50-10:05 a.m. | American Ballroom Foyer

Plenary Session 8: Clinical and Biological Intersection

10:05 a.m.-12:15 p.m. | America Ballroom North | CME Eligible

Session Chair: Fernando Vidal-Vanaclocha, The George Washington University, Washington, DC

  • 10:10 a.m. | Leveraging the immune system for pancreatic cancer interception in high-risk cohorts
    Neeha A. Zaidi, Johns Hopkins Medicine, Baltimore, Maryland
  • 10:40 a.m. | Integrating clinical and laboratory research to identify mechanisms of response and resistance to immune checkpoint therapy
    Padmanee Sharma, The University of Texas MD Anderson Cancer Center, Houston, Texas
  • 11:10 a.m. | Diffuse large B-cell lymphoma and neurotoxicity following CAR-T cell immunotherapy: Contributing factors and Blood-brain barrier impairment biomarkers
    Fernando Vidal-Vanaclocha
  • 11:40 a.m. | Fc-optimized agonistic CD40 antibody induces tumor rejection and systemic antitumor  immunity: From the bench to the bedside and back*
    Polina Weitzenfeld, The Rockefeller University, New York, New York
  • 11:55 a.m. | Panel Discussion

Closing Remarks/departure

12:15 p.m.